Ryvu Therapeutics and nCage Therapeutics have announced a research collaboration to develop a next-generation antibody-drug conjugate (ADC) platform.
 
nCage’s TRAP cage platform, a novel drug delivery system (DDS), could enhance the efficacy and safety of current ADCs. By utilizing virus-like particles (VLPs), the platform can improve the antibody-to-drug ratio (DAR) of ADCs, potentially leading to greater efficacy and reduced side effects.
 
“This collaboration is an exciting opportunity to combine our small molecule expertise and experience with novel ADC payloads with the strong team at nCage,” said Krzysztof Brzózka, Ryvu’s Chief Scientific Officer. “We are encouraged by the growing field of next-generation ADCs and the potential for this collaboration to generate more effective and safer therapies.”  
 
nCage CEO, John Bason, added: “Our promising vaccine data suggests that we can develop best-in-class products for numerous viral targets. We are excited about the potential for this partnership with Ryvu to help us develop a second arm of the company, further driving the development of the company.”
 
The two companies will jointly own all data generated through the collaboration and will share costs. They expect to provide further updates on the partnership as the work progresses.